Gel-Based Delivery System Development
Liposomes are a novel drug delivery system. They are bimolecular vesicle structures that form spontaneously when phospholipids are dispersed in water. At Alfa Cytology, we have established a proprietary liposome platform to accommodate the increasing demand of novel liposome preparations.
Introduction to Liposome Drug Delivery System for Bladder Cancer
Non-muscle-invasive bladder cancer comprises the majority of cases in bladder cancer and is typically treated with transurethral resection of bladder tumor (TURBT) followed by intravesical therapy, such as chemotherapy or immunotherapy. However, current intravesical therapies face limitations in terms of drug permeation, residence time, and patient compliance. To overcome these challenges, researchers have been focusing on the development of innovative drug delivery systems (DDS) that can enhance drug residence, improve permeation capacity, and enable targeted drug release.
Fig 1. Common novel gel-based delivery systems. (Sastri, T. K., and et al. 2022)
One promising approach is the utilization of gel-based drug delivery systems, which offer several advantages in the treatment of bladder cancer.
- Enhanced Drug Residence Time
- Improved Drug Permeation
- Targeted Drug Release
- Customizable Formulations
- Potential for Combination Therapies
- Minimized Systemic Side Effects
Our Services
Alfa Cytology, a leading company in preclinical contract research organization (CRO) services, offers a comprehensive range of services to facilitate the development of liposomal drug delivery systems for bladder cancer. Our liposomal drug delivery system technology services leverage cutting-edge technology to optimize and customize liposomal formulations for specific therapeutic applications.
 |
 |
 |
| Intelligent Hydrogels Development |
In Situ Gels Development |
Emulsion Gels Development |
| The temperature-responsive, pH-responsive, light-responsive, and electric-field-responsive hydrogels and etc. are designed. |
We specialize in the development of in situ gels tailored for bladder cancer treatment, optimizing gel composition and gelation kinetics to achieve optimal drug delivery outcomes. |
We excel in the development of emulsion gels for bladder cancer therapy, formulating stable emulsions and designing gel matrices to achieve controlled drug release and improved therapeutic efficacy. |
- Site-specific drug release;
- Minimizing off-target effects;
- Enhancing therapeutic efficacy.
|
- Prolonged drug residence time;
- Controlled drug release;
- Improved drug permeation.
|
- Enhance drug solubility;
- Enhance drug stability;
- Controlled drug release.
|
 |
 |
 |
| Microgels Development |
Nanogels Development |
Vesicular Gels Development |
| By optimizing the size, composition, and surface properties of microgels, we can provide microgels tailored for bladder cancer to enhance drug permeation and achieve targeted drug delivery to the bladder. |
We provide our clients with nanosized hydrogel particles that can encapsulate drugs and deliver them to the target site. |
Vesicular gels, also known as lipogels, are designed utilizing the unique characteristics of liposomes and hydrogels to optimize drug delivery efficiency. |
- Encapsulate drugs;
- Protect drugs from degradation;
- Controlled drug release.
|
- High stability;
- Tunable size;
- Stimuli-responsive behavior.
|
- High drug-loading capacity;
- Protection of drugs from degradation;
- Sustained drug release.
|
Contact Us
Gel-based drug delivery systems offer significant potential for improving the treatment of bladder cancer. Alfa Cytology, as a leading company in the field, provides a wide range of specialized services for the development of gel-based drug delivery systems, including intelligent hydrogels, in situ gels, emulsion gels, microgels, nanogels, and vesicular gels. If you have any needs, please contact us today.
Reference
- Diana G., Artur C. P., and et al. Design of liposomes as drug delivery system for therapeutic applications. International Journal of Pharmaceutics. 2021, 601,120571.
For research use only. Not intended for any clinical use.
Related Services
